Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib plus VRD in newly diagnosed multiple myeloma
NCT06799676Phase 2Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linperlisib in multiple myeloma (MM). Primary endpoints: Dose-Limiting Toxicity at Cycle 4 and Very Good Partial Response Rate at Cycle 4. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
linperlisib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06799676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799676.